BeaconEquity.com: Sangamo Biosciences (SGMO) Shares Fall on Study Failure
Shares of Sangamo Biosciences Inc., a biotechnology company engaged in the research, development and commercialization of DNA-binding proteins, are down sharply in today’s trading after the company announced that its phase IIb trial of SB-509 in diabetic neuropathy did not meet key study endpoints. At last check, Sangamo Biosciences shares were trading 23.45% lower at $3.33, with volume up from daily average of 604,766 to 1.86 million. Sangamo said that the phase IIb trial results showed that SB-509 treatment did not show statistically significant improvements from baseline when compared with placebo at 180 days in the primary endpoint. Dale Ando,…